With a continuing interest on heteropolycyclic structures which may show biological activities, we synthesized new tricyclic derivatives in which the pyridopyrazine skeleton is fused with pyrazine 7 and 8, B, n = 1. However, the initial design of obtaining also the cyclohomologous structure B (n = 2) produced instead a pyranopyridopyrazine derivative 11. Thus during the attempt to prepare a pyridodiazepine
随着对杂多环结构一个持续的兴趣,其可以示出
生物活性,我们合成了其中
吡啶并
吡嗪骨架稠合
吡嗪与新
三环衍
生物7和8,B中,n = 1。然而,也获得cyclohomologous结构的初始设计乙( n = 2)代替生成
吡喃并
吡啶并
吡嗪衍
生物11。因此,在尝试制备
吡啶二氮杂中间体的过程中,除了非常少量的所需产物10之外,还获得了
吡啶并
吡嗪9。后者化合物与反应
氯乙酰氯/ chloroketene,得到4-乙氧羰基-10-(
氯乙酰基)-5,10-二氢-5-甲基-2- ħ
吡喃并[2,3-b ] pyrido [2,3 - e ] pyrazin-2-one(11)。在研究该衍
生物的行为时,获得了化合物12-14。化合物4b,c,5a,b,7、8、9和14已作为CNS
抑制剂进行了初步的药理筛选。